Oncology, Institut Curie, Paris, France, 5Oncology, Institut Jean Godinot, Reims, France, 6Oncology, Centre Léonard de Vinci, Dechy,France, 7Oncology, Pole Sante Republique, Clermont-Ferrand, France, 8OncologieMédicale, Institute Paoli Calmettes, Marseille, France, 9Oncology, Centre Catherine de Sienne, Nantes, France, 10Oncology, Centre Claudius-Regaud,Toulouse, France, 11Oncology, Centre d'Oncologie de Gentilly, Nancy, France,12Clinical research, Laboratoire Roche, Boulogne-Billancourt, France, 13Statisticalresearch department, Laboratoire Roche, Boulogne-Billancourt, France, 14MedicalOncology Department, Assistance Publique Hôpitaux de Paris -Tenon, Paris,France Background: HANNAH (NCT00950300) and PREFHER (NCT01401166) international, randomised studies validated the subcutaneous (SC) formulation of trastuzumab as effective and safe as intravenous (IV) and highly preferred by patients in early breast cancer. The present randomized Metaspher trial (NCT 01810393) assessed patient's preference in metastatic setting. Methods: Patients with HER2-positive metastatic breast cancer who completed a firstline chemotherapy with trastuzumab (IV) and achieved a long term response lasting more than 3 years were randomised to receive 3 cycles of 600 mg fixed-dose adjuvant trastuzumab SC, followed by 3 cycles of standard IV, or the reverse sequence. Primary endpoint was overall preference for SC or IV at cycle 6, assessed by Patient Preference Questionnaire (PPQ). Secondary endpoints included healthcare professional (HCP)satisfaction, assessed by questionnaire; safety and tolerability, assessed by NCI-CTCAEv4.0; quality of life assessed by QLQ C30 questionnaire. The modified-Intent-To-Treat population (m-ITT) included patients who received both routes of administration and who completed the last question of PPQ. The safety population included all enrolled patients who received at least one dose of treatment. Results: 113 patients were randomised. SC was preferred by 79/92 evaluable m-ITT patients (85.9%, 95% CI [78.8; 93 .0]; p < 0·001), 13 preferred IV (14.1%, 95% CI[7.0; 21.3] ). Among patients without preference at baseline (52/89 available data), SC was preferred by 46/52 patients (88,5%, [79.8;97.2] ). HCP were most satisfied with SC(56/88 available data, 63.6%, [53.6;73.7] ). On the safety population, 108 patients received SC and 111 received IV. Clinician-reported adverse events occurred in 73(67.6%) and 49 (44·1%) patients during the SC and IV periods, respectively; 7 (6.5%)and 4 (3.6%) were grade ≥ 3, 3 (2·8%) and 2 (1·8%) were serious. Conclusions: Patients preferred trastuzumab SC. The safety profile was consistent with the known IV profile with no safety concerns raised. Next step will assess the follow up of this cohort of long responder patient with metastatic breast cancer. Clinical trial identification: NCT 01810393 Legal entity responsible for the study: 
Developmental Therapeutics 375P A phase Ib dose-finding study of alpelisib (ALP; BYL719) andpaclitaxel (PTX) in advanced solid tumors (aST)
Hanover, NJ, USA, 7Oncology GlobalDevelopment, Novartis Pharma AG, Basel, Switzerland, 8Oncology, HighlandsOncology Group, Lafayetteville, AZ, USA Background: Aberrant activation of the phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin pathway due to alterations in PIK3CA (encodingPI3Kα) frequently occurs in aST.We report safety findings from an ongoing, phase Ibdose-escalation study of ALP (PI3Kα inhibitor) + PTX (NCT02051751). Methods: Patients ( pts) aged ≥18 years with aST (not amenable to resection/progressed on standard therapy), ECOG performance status ≤2, adequate bonemarrow/organ function, and no prior treatment with PI3K or AKT inhibitors wererecruited. The primary objective was to determine the maximum tolerated dose (MTD)and/or recommended Phase II dose of ALP + PTX based on dose-limiting toxicities(DLTs) in Cycle 1. Dose escalation of ALP was guided by an adaptive Bayesian logisticregression model with escalation with overdose control principle. Results: As of Dec 7, 2015, 19 pts received oral ALP (300 mg [n = 6], 250 mg [n = 4], or150 mg [n = 9] once daily [QD]) and IV PTX (80 mg/m2 once weekly [QW]). Themost common primary sites of cancer were breast (n = 5) and rectum (n = 3).Treatment was discontinued in 18/19 pts due to disease progression (n = 12, 63%), ptdecision (n = 3, 16%), adverse events (AEs; n = 2, 11%; 1 pt for grade [G]3 dehydration,G3 hyperglycemia, and G3 acute kidney injury; 1 pt for G4 neutropenia and G4γ-glutamyltransferase increase), and physician decision (n = 1, 5%). DLTs occurred in5/12 pts in the dose-determining set: 1/1 (100%) pt at 300 mg QD, 2/3 (67%) pts at250 mg QD, and 2/8 (25%) pts at 150 mg QD. Six DLTs were reported: G2hyperglycemia (n = 3), G4 hyperglycemia, G4 leukopenia, and G3 acute kidney injury(each n = 1). The MTD of ALP + PTX (80 mg/m2 QW) was declared as 150 mg QD.All 19 pts had ≥1 treatment-emergent AE. Grade 3/4 AEs occurred in 11 (58%) pts, the most frequent being hyperglycemia (n = 6, 32%), diarrhea, anemia, lymphopenia, neutropenia, and leukopenia (each n = 2, 11%).
Conclusions:
In pts with aST, the MTD of ALP + PTX (80 mg/m2 QW) was 150 mgQD. Due to the challenging safety profile of the combination and lack of available data confirming the pharmacodynamics and/or clinical activity of ALP at 150 mg QD,planned dose expansion in pts with breast cancer and head and neck squamous cellcarcinoma will not go forward. Clinical trial identification: NCT02051751 Legal entity responsible for the study: Novartis Funding: Novartis Disclosure: J. Rodón: Advisory board for Novartis, Lily, Servier, Leti, Oncompass,Orion Pharma. V. Donnet: Novartis Full-time Employee. Y. Han: I am an employee atNovartis and receive a salary from Novartis. L. Blumenstein: I hereby confirm to be aNovartis Pharma AG employee with stock ownership. C. Wilke: Employee of NovartisAG, sponsor of the study. All other authors have declared no conflicts of interest.
397P Phase 1 study of sorafenib and eribulin in patients withadvanced, metastatic or refractory solid tumors F. Marmé1, C. Gomez-Roca2, K. Graudenz3, F. Huang4, J. Lettieri5, C. Pena4,Z. Trnkova3, J. Eucker6 1Translationale Gynäkologische Onkologie, Universitätsklinikum Heidelberg &Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany, 2MedicalOncology, Institut Claudius Regaud, Toulouse, France, 3Clinical Pharmacology,Oncology, Bayer Pharma AG, Berlin, Germany, 4Clinical Pharmacology, Oncology,Bayer Healthcare Pharmaceuticals, Whippany, NJ, USA, 5ClinicalPharmacokinetics, Pharmacodynamics, Bayer Healthcare Pharmaceuticals,Whippany, NJ, USA, 6Onkologie und Hämatologie, Universitätsmedizin Berlin,Berlin, Germany Background: Combining sorafenib (SOR), an oral multikinase inhibitor approved forhepatocellular carcinoma, renal cell carcinoma, and differentiated thyroid carcinoma, with eribulin mesylate (ERI), a microtubule inhibitor approved for breast cancer (BC), may provide synergistic antitumor activities. Methods: This phase 1b, open label, dose escalation study evaluated safety,pharmacokinetics (PK), maximum tolerated dose/recommended phase 2 dose (MTD/RP2D), cardiac safety (QT/QTc), and preliminary efficacy of SOR + standard dose ERI(1.4 mg/kg IV on Days [D] 1 and 8 of each 21-day cycle [C]) in patients ( pts) with advanced, metastatic, or refractory tumors. Starting SOR dose was 200 mg BID continuously starting on D11 of C1. SOR + ERI-related hematologic and non hematologic dose limiting toxicities (DLT) were assessed in C2. If tolerable, SOR was escalated in new cohorts to 600 mg daily (200 mg AM/400 mg PM) and 400 mgBID. QT/QTc intervals and PK were evaluated respectively in C1 for single dose andC2 for multiple doses. Antitumor activity was assessed by RECIST v1.1. RP2D was confirmed in a MTD expansion cohort (minimum 12 pts). Results: Of 40 pts treated, 5 received SOR 200 mg BID, 8 received 600 mg/d, and 27received 400 mg BID (MTD), of whom 14 were in the expansion cohort. Of 12 cancer types reported, 62.5% of pts had BC. No DLT was reported in the 200-mg and 600-mgcohorts; 1 DLT (Grade 3 increased ALT) was reported in the 400-mg BID dose escalation cohort and 1 DLT (Grade 3 acute coronary syndrome) in the expansion cohort. Most common drug-related ≥Grade 3 TEAEs were hypophosphatemia (10%)and hypertension (10%) for SOR and neutropenia (25%) for ERI. No significant QT/QTc prolongation was observed; mean QTcF change from baseline was 11.44 ms with ERI alone and 8.25 ms with ERI + SOR. No drug interaction was observed; mean SORAUC was 60.4 mg*h/L for SOR 400 mg BID + ERI and 56.7 mg*h/L for SOR 400 mgBID alone. Respective mean SOR Cmax were 6.8 and 7.7 mg/L. 8 pts had a partial response (5 confirmed, 3 unconfirmed). Conclusions: SOR 400 mg BID + standard dose ERI was well tolerated and confirmedRP2D. Toxicities were in line with known SOR and ERI safety profiles. Thus,SOR + ERI would be appropriate to examine in larger studies. Research Unit, ICM Regional Cancer Institute of Montpellier,Montpellier, France, 15Anatomo-Pathology Department, ICM Regional CancerInstitute of Montpellier, Montpellier, France, 16Pharmacology Department, ICM Regional Cancer Institute of Montpellier, Montpellier, France Background: Sorafenib and irinotecan combination (NEXIRI) showed promising efficacy with a 65% disease control rate (DCR) in pretreated mutated (mt) KRASmCRC. In our previous single-arm phase II study, CCND1 rs9344 A/A polymorphism was found to be a candidate predictive biomarker (Samalin et al. 2014) . Our multicentre randomized phase II trial aimed to determine the 2-monthprogression-free survival (2-PFS) of NEXIRI vs Iri or Soraf monotherapies in these patients after failure of all approved active drugs at the time of the study. Methods: Patients PS ≤ 1 with progressive non-resectable mtKRAS (then RAS) mCRCpretreated with irinotecan, oxaliplatin, fluoropyrimidines and bevacizumab (none with regorafenib), were randomized in 3 arms: NEXIRI (biweekly Iri IV 120, 150, 180mg/m2at C3 combined with a fixed dose of 400mg Soraf twice daily) vs Iri (180mg/m2) alonevs Soraf alone, until progression or toxicity, with cross-over to NEXIRI at progression. Primary endpoint was the 2-PFS (RECIST v1.1). Pharmacokinetic, pharmacogenetics and tissular ancillary studies were performed. Results:We included 173 patients (age 62 years [31-82]; PS 0/1: 38/61%) betweenJanuary 2012 and July 2014 in 17 French centres. Main results were (median follow-up 17.5 months): Conclusions: In this randomized study, we confirmed the NEXIRI regimen efficacy for refractory mtRAS mCRC patients and the predictive value of CCND1 rs9344 which may identify patients who benefit from this combination. These results justify comparing NEXIRI to regorafenib monotherapy in CCND1 rs9344 A/A patients. Clinical trial identification: The trial was registered on nicaltrials.gov:NCT01715441 Legal entity responsible for the study: We report here the results of the planned interim analysis on toxicity plus those on efficacy as the trial closed prematurely. Methods: Inclusion criteria: patients ( pts) with LMCRC after failure to a 1st line of IVCT; ECOG performance status (PS) 0 or 1; at least one liver lesion evaluable by RECIST; extra-hepatic disease acceptable when limited to one or two lung metastases or lymph nodes potentially accessible to a curative treatment. They had to receive IAH treatment with B, 7.5 mg/kg every 3 weeks, and systemic CT with capecitabine (2 g/m2/day (d) 14 d, followed by 7 d rest) + irinotecan (200 mg/m2 every 21d) or oxaliplati n(130 mg/m2 every 21 d) depending on the 1st line received. Results: Between 06:2013 and 02/2015, 10 pts from 5 centers were included: 6 men, 4women (median age 61 years); ECOG PS0 (7) and PS1 (3); limited extra-hepatic disease in 4 pts. Median duration of 1st line treatment was 6 months. IAH catheter was implanted surgically in one pt and radiologically in 9. Pts had an average of 6 cycles o fIAH B, 3 received oxaliplatin and 7 irinotecan concomitantly. There was one grade (G)3 allergic reaction to IAH B, one G3 abdominal pain, one G3 mucositis, one G3 nausea and one G3 vomiting events. Related to the use of B, 2 G3 thromboembolic events and3 G3 hypertension were observed. The arterial catheter has to be replaced in one pt and a thrombosis of hepatic artery was observed in a second one preventing continuation of IAH treatment after one cycle. In the 9 evaluable pts, 2 had partial response (22%), 5stable disease (56%) and 2 progressive disease (22%). The median progression-free and overall survival were 5.2 months 95%CI [1.6 -6.2] and 13.5 months [4.8 -NR]. Conclusions: IAH administration of bevacizumab in pts with LMCRC seems to be feasible with no major side effect. The efficacy reported did not suggest a major effect o fthis treatment that should rather be used in combination with IAHCT with oxaliplatin. We thank the PHRC for its financial support 
endocrine and neuroendocrine tumours 416O Efficacy and safety of pasireotide LAR or everolimus alone, orin combination in patients with advanced carcinoids (NET) ofthe lung/thymus: Results from the randomized, phase 2 LUNA study
P. Ferolla1, M.P. Brizzi2, T. Meyer3, W. Mansoor4, J. Mazieres5, C.D. Cao6,H. Lena7, A. Berruti8, V. Damiano9, W. Buikhuisen10, M. Stankovic11, N. Singh12, E. Chiodini13, G. Gislimberti14, K. Oberg15, E.F-C. Bidard1, M. Ychou2, J. Madic3, A. Saliou3, O. Bouché4, M. Rivoire5,F. Ghiringhelli6, E. Francois7, R. Guimbaud8, L. Mineur9, F. Khemissa-Akouz10,T. Mazard2, D. Moussata11, W. Cacheux1, C. Proudhon3, M-H. Stern12,J-Y. Pierga1, T. Stanbury13,
genitourinary tumours, prostate 722PD PROSELICA: Health-related quality of life (HRQL) andpost-hoc analyses for the phase 3 study assessingcabazitaxel 20 (C20) vs 25 (C25) mg/m2 post-docetaxel (D) inpatients (pts) with metastatic castration-resistant prostatecancer (mCRPC)
Kenilworth, NJ, USA, 13Biostats, Merck & Co., Inc.,Kenilworth, NJ, USA, 14Oncology, Merck & Co., Inc., Kenilworth, NJ, USA,15Department of Investigational Cancer Therapeutics, UT MD Anderson CancerCenter, Houston, TX, USA Background: Therapies currently available for castrate-refractory prostate cancer(CRPC) provide only modest clinical benefit. Expression of the programmed death 1(PD-1) receptor and its ligand, PD-L1, has been reported in CRPC. Pembrolizumab, ananti-PD-1 antibody, blocks the interaction between PD-1 and PD-L1. KEYNOTE-028(NCT02054806) is a nonrandomized, phase 1b trial to evaluate the safety and efficacy yof pembrolizumab in 20 advanced solid tumor cohorts. Herein are the results from the prostate adenocarcinoma cohort of this study. Methods: Key eligibility criteria included advanced adenocarcinoma of the prostate, failure of standard therapy, measurable disease per RECIST v1.1, ECOG PS 0-1, andPD-L1 expression in ≥1% of tumor or stroma cells by immunohistochemistry. Pembrolizumab 10 mg/kg was administered every 2 weeks (wk) for up to 24 months(mo) or until disease progression (PD), intolerable toxicity, death, or withdrawal of consent. Stable patients ( pts) with PD could remain on treatment until PD was confirmed by a follow-up scan. Response was assessed every 8 wk for the first 6 mo and every 12 wk thereafter. The primary end point was ORR per RECIST v1.1 by investigator review. As an exploratory objective, a NanoString platform was used to assess baseline tumor tissue for the gene expression profile (GEP) of an 18-gene panel hypothesized to be associated with a Th1-derived IFN-γ immune response. Results: Of the 23 pts enrolled in this cohort, median age was 65 years, 74% had an ECOG PS of 1 (1 pt had an ECOG PS of 2), and 74% received ≥2 prior therapies for metastatic disease. As of February 17, 2016, median follow-up duration was 33 wk(range, 6-79 wk). Fourteen pts (61%) had treatment-related adverse events (TRAEs),most commonly nausea (n = 3, 13%). Three pts (13%) had grade 3-4 TRAEs; 1 pt had grade 3 fatigue, 1 pt had grade 3 peripheral neuropathy, and 1 pt had grade 3 asthenia and grade 4 lipase increase. No pts died or discontinued pembrolizumab because of aTRAE. Three pts had a confirmed PR, for an ORR of 13% (95% CI, 3%-34%); median duration of response was 59 wk (range, 28-62 wk). Stable disease rate was 39% (n = 9;95% CI, 20%-61%). Median OS was 8 mo, and the 6mo PFS rate was 39%. Two pts remained on treatment at data cutoff. Exploratory assessment of the relationship between GEP score and clinical outcome revealed the putative T cell inflamed signature to be associated with better clinical outcome, consistent with pembrolizumab findings published previously. Since 2015, docetaxel chemotherapy, combined with ADT, is consideredthe standard of care in fit men with metastatic hormone-naive prostate cancer (mHNPC), based on data from three phase III trials CHAARTED, and STAMPEDE) . No data are currently available regarding activity of treatments used beyond progression after upfront ADT and docetaxel. Methods:We retrospectively collected data from patients ( pts) participating in the GETUG-AFU 15 phase III trial concerning treatments received beyond progression for castration-resistant disease (CRPC) in both arms (ADT and ADT + docetaxel)including treatment efficacy (measured by a PSA decline, physician assessment ofclinical benefit, and time to events), and toxicity (NCI-CTC grading). Results: 245 pts received at least one anticancer treatment at CRPC progression. The treatments most frequently used and their efficacy are detailed in the Table. Toxicity was mild, with only rare grade 3-4 events (17%). Median overall survival measured after the onset of CRPC was respectively 2.29 years (IC95% [1.84-2.59]) and 1.97 years (IC95% [1.64-2.73]) in the ADT and ADT + D arms.
Conclusions:
In this retrospective analysis, anticancer activity was suggested with androgen receptor axis-targeted agents even in patients with metastatic prostate cancer treated upfront with ADT + docetaxel. We observed that docetaxel rechallenge had rather limited activity in this setting. Clinical trial identification: NCT00104715; release date: 2013 Februray (LancetOncol) Legal entity responsible for the study: Unicancer Funding: French Health Ministry and Institut National du Cancer (PHRC),Sanofi-Aventis, AstraZeneca, and Amgen Disclosure: F. Joly: Roche, Pfizer, Novartis, Sanofi, Jansen, Astellas.M. Soulié: Amgen,Astellas, Astra Zeneca, Ferring, Glaxo Smith K, Ipsen, Jansen, Keocyt, Novartis, PierreFabre, Sanofi, Takeda, Zambon.B. Laguerre: Pfizer, Novartis, Jansen.K. Fizazi:Participation to advisory boards and honorarium : Sanofi, Janssen, Astellas.All otherauthors have declared no conflicts of interest.
genitourinary tumours, prostate 829P Denosumab in patients with bone metastases from renal-cellcarcinoma treated with anti-angiogenic therapy:a retrospective study from the GETUG (Groupe Etude desTumeurs Uro Genitales)
A. Guillot1, C. Joly2, P. Barthelemy3 Loire, Saint Priest En Jarez, France Background: Metastatic renal-cell carcinoma (mRCC) treatment relies onanti-angiogenic therapies. Bone metastases occur in nearly 30% of mRCC and caninduce symptomatic skeletal-events (SSE) such as pain requiring radiotherapy, pathologic fractures, and spinal cord compression. SSE can be prevented using bone-targeted agents, e.g. bisphosphonates or denosumab. Data about denosumab and anti-angiogenic combination are scarce. Methods: This multicenter retrospective study led by GETUG included mRCC patients ( pts) who received anti-angiogenic therapies associated with denosumab from January 2013 to December 2015. The primary endpoint was toxicity related todenosumab, especially osteonecrosis of the jaw (ONJ) and hypocalcaemia. Results: 37 pts were identified and 36 analyzed. The mean age was 60.9 year-old (range42-81). Twenty-four pts (68%) had an odontological consultation before denosumab introduction and 20 pts (58.3%) had a dental panoramic radiography. Five pts (13.9%) developed an ONJ, among them 3 had a dental extraction while on denosumab treatment. Only one out of the 5 pts has completely recovered from his ONJ. No grade3-4 hypocalcaemia was reported. SSE occurred in 22 pts (61.1%) including bone pain requiring radiation, clinical fractures, and spinal compression in 22, 3, and 2 pts, respectively. Conclusions: In this real life population, the incidence of SSE was very high in mRCCpts with bone metastases. The combination of denosumab with anti-angiogenic drugs was associated with a high incidence of ONJ that may have been favored by denta lextraction while on treatment. The present study underlines the need to improvestrategies to prevent the onset of SSE in this population of pts. Legal entity responsible for the study: N/A Funding: GETUG Disclosure: A. Guillot: board PFIZER. S. Negrier: honoraria from Pfizer, Novartis etBMS. D. Pouessel: Board: roche, astellas, Lilly, Novartis, Sanofi Advisory: MSD,AstraZeneca. Speaker : Astellas, Janssen, Boehringer-ingelheim, Sanofi. C. Chevreau:board advisory: Pharmamar Inc, Novartis Inc. L. Albiges: consultaant or advisory role:novartis, pfizer, amgen, BMS, Bayer, Sanofi, Cerulean. K. Fizazi: consultant/advisor forAmgen Inc.,Novartis,Clovis, Pfizer, CSL, Behring, and Bayer-GlaxoSmithKline, andGenentech-speakers' bureau for Genomic Health research funding from Amgen Inc.,Novartis, Bayer, and Puma. All other authors have declared no conflicts of interest.
gynaecological cancers 859PD The CHIVA study: a GINECO randomized double blind phase IItrial of nintedanib versus placebo with the neo-adjuvant chemotherapy (NACT) strategy for patients (pts) with advanced unresectable ovarian cancer (OC). Report of theinterval debulking surgery (IDS) safety outcome
